Advertisement
Canada markets open in 4 hours 57 minutes

  • S&P/TSX

    22,011.62
    +42.38 (+0.19%)
     

  • S&P 500

    5,116.17
    +16.21 (+0.32%)
     

  • DOW

    38,386.09
    +146.43 (+0.38%)
     

  • CAD/USD

    0.7303
    -0.0019 (-0.26%)
     

  • CRUDE OIL

    82.68
    +0.05 (+0.06%)
     

  • Bitcoin CAD

    86,000.88
    -925.06 (-1.06%)
     

  • CMC Crypto 200

    1,313.19
    -25.88 (-1.93%)
     

  • GOLD FUTURES

    2,326.20
    -31.50 (-1.34%)
     

  • RUSSELL 2000

    2,016.03
    +14.03 (+0.70%)
     

  • 10-Yr Bond

    4.6140
    -0.0550 (-1.18%)
     

  • NASDAQ futures

    17,888.00
    -16.25 (-0.09%)
     

  • VOLATILITY

    14.82
    +0.15 (+1.02%)
     

  • FTSE

    8,172.95
    +25.92 (+0.32%)
     

  • NIKKEI 225

    38,405.66
    +470.90 (+1.24%)
     

  • CAD/EUR

    0.6821
    -0.0003 (-0.04%)
     

Ascletis Announces Strategic Decisions on FXR agonist ASC42

PR Newswire
·2 min read

HANGZHOU, China and SHAOXING, China, April 3, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today the strategic decisions on farnesoid X receptor (FXR) agonist ASC42.

After thorough analysis of the Phase II trial data of ASC42 for primary biliary cholangitis (PBC) (ClinicalTrials.gov: NCT05190523), the Company made a strategic decision not to pursue further clinical trials of ASC42 for PBC indication. This decision is based on the efficacy and safety data from the 12-week Phase II study, which consisted of three ASC42 active treatment arms (5 mg, 10 mg and 15 mg QD) and one placebo control arm. The results indicated that ASC42 did not show competitiveness to new PBC drug candidates currently in development and registrational stages.

Furthermore, the Company also decided not to pursue further clinical studies of ASC42 as an FXR agonist in combination for non-alcoholic steatohepatitis (NASH) (ASC43F) and clinical studies of ASC42 for hepatitis B virus (HBV) indication.

As of December 31, 2023, the Group had cash and cash equivalent and time deposits of approximately RMB 2.3 billion. These strategic decisions are part of the Company's efforts to continue to evaluate and optimize its research & development pipeline to increase efficiency and preserve cash. The savings from discontinuing these planned clinical trials will be used to accelerate clinical development of ASC41 and ASC40 for NASH indication and in-house discovery for global first-in-class or best-in-class drug candidates. The positive interim results from ASC41 Phase II trial in biopsy-confirmed NASH patients demonstrated ASC41 as a potential best-in-class thyroid hormone receptor β (THRβ) agonist. As a first-in-class FASN inhibitor, the Phase IIb study showed ASC40 (denifanstat) achieved statistically significant results for both NASH resolution and fibrosis improvement in biopsy-confirmed NASH patients with stage 2 or 3 fibrosis after 52-week treatment.

ADVERTISEMENT

About Ascletis

Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to manufacturing and commercialization. Led by a management team with deep expertise and a proven track record, Ascletis focuses on three therapeutic areas with unmet medical needs from a global perspective: viral diseases, non-alcoholic steatohepatitis (NASH) and oncology. Through excellent execution, Ascletis rapidly advances its drug pipeline with an aim of leading in global competition. To date, Ascletis has multiple drug candidates in its R&D pipeline. The most advanced drug candidates include ASC22 (CHB functional cure), ASC40 (acne), ASC40 (recurrent glioblastoma), ASC40 (NASH), ASC41 (NASH) and ASC61 (advanced solid tumors).

For more information, please visit www.ascletis.com.

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/ascletis-announces-strategic-decisions-on-fxr-agonist-asc42-302107029.html

SOURCE Ascletis Pharma Inc.